Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis

Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates ruxolitinib's efficacy and safety against best available therapy (BAT) in patients with PV and in hydroxyurea‐resistant/int...

Full description

Saved in:
Bibliographic Details
Published in:APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2024-11, Vol.132 (11), p.775-786
Main Authors: Roca Mora, M. Meritxell, Afzal, Farhan, Guimaraes, Catharina Ribeiro, Cunha, Luisa Marin, Godoi, Amanda, Marcolin, Patrícia, Valenzuela S, Andrés
Format: Article
Language:English
Subjects:
Anemia
Cancer
Effectiveness
Hematocrit
Herpes zoster
Humans
Hydroxyurea
Hydroxyurea - adverse effects
Hydroxyurea - therapeutic use
JAK inhibitor
Janus kinase
Janus Kinase 1 - antagonists & inhibitors
Janus kinase 2
Janus Kinase 2 - antagonists & inhibitors
Literature reviews
Meta-analysis
myeloproliferative neoplasm
Neoplasms
Nitriles - therapeutic use
Polycythemia
Polycythemia vera
Polycythemia Vera - drug therapy
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - therapeutic use
ruxolitinib
Safety
Skin cancer
Skin resistance
Subgroups
Thromboembolism
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates ruxolitinib's efficacy and safety against best available therapy (BAT) in patients with PV and in hydroxyurea‐resistant/intolerant PV patients. A comprehensive literature search was conducted up to November 2023. We compared ruxolitinib and BAT for efficacy and safety endpoints. Six studies involving 1061 patients were analyzed, with 620 on BAT and 441 on ruxolitinib. Ruxolitinib showed higher hematocrit control (p = 0.015) and treatment response (p = 0.04) compared to BAT. It also significantly improved Myeloproliferative Neoplasms‐Symptom Assessment Form scores (MPN‐SAF) (p 
ISSN:0903-4641
1600-0463
1600-0463
DOI:10.1111/apm.13472